Operating Expenses változás Dátum
Acadia Pharmaceuticals USD 196.1M 73.38M 2023-12
ALKERMES USD 337.09M 41.11M 2023-09
Alnylam Pharmaceuticals USD 556.12M 19.46M 2023-12
Biogen USD 2.03B 344.1M 2023-12
BioMarin Pharmaceutical USD 631.99M 76.32M 2023-12
Bristol-Myers Squibb USD 9.62B 984M 2023-12
Cara Therapeutics USD 33.76M 5.51M 2023-09
Corcept Therapeutics USD 103.74M 11.31M 2023-12
Cytokinetics USD 129.09M 6.45M 2023-12
Eisai JPY 171.22B 309M 2023-09
Eli Lilly USD 6.97B 2.08B 2023-12
Incyte USD 826.07M 121.75M 2023-12
Intra Cellular Therapies USD 166.2M 10.31M 2023-12
J&J USD 16.57B 435M 2023-12
Marinus Pharmaceuticals USD 38.98M 1.46M 2023-09
Moderna USD 2.8B 1.04B 2023-12
Neurocrine Biosciences USD 357.6M 21.5M 2023-09
Pfizer USD 20.8B 4.62B 2023-12
PTC Therapeutics USD 438.79M 124.05M 2023-12
Sarepta Therapeutics USD 380.16M 87.4M 2023-09
Ultragenyx Pharmaceutical USD 249.44M 6.29M 2023-12
Vanda Pharmaceuticals USD 48.92M 11.57M 2023-06
Vertex Pharmaceuticals USD 1.45B 21.4M 2023-09



Acadia Pharmaceuticals Üzemeltetési Költségek - Az oldal aktuális és múlbeli adatokat, elorejelzéseket, statisztikákat, grafikonokat és a gazdasági naptár adatait tartalmazza - Mar 2024.